OncoMatch/Clinical Trials/NCT06122493
Optimization of Treatment Strategy for Unresectable cN3 Esophageal Squamous Cell Carcinoma
Is NCT06122493 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Tirelizumab and Nab paclitaxel for esophageal squamous cell carcinoma.
Treatment: Tirelizumab · Nab paclitaxel · Carboplatin — This study aims to investigate a comprehensive therapeutic approach for patients with unresectable esophageal squamous cell carcinoma, clinically staged as Tany, N3, M0, and who are not candidate for concurrent chemoradiotherapy combined with immunotherapy. The approach entails combining chemotherapy with immune therapy, followed by synchronized radiotherapy during the immune maintenance phase. The primary goal is to mitigate treatment-related side effects and enhance the overall prognosis through the integration of these treatment modalities.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Esophageal Carcinoma
Disease stage
Required: Stage ANY T, N3M0 (AJCC/UICC eighth edition)
Locally advanced stage: AJCC/UICC eighth edition staging with any T, N3M0.
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Cannot have received: radiation therapy
Lab requirements
Blood counts
Hemoglobin ≥100g/L, platelets ≥90×10^9/L, white blood cells ≥4×10^9/L. Exceptions: ECOG 0-1 with chronic anemia (80-100 g/L), previous low WBC (3-4×10^9/L), or reduced platelets (80-90×10^9/L)
Kidney function
Serum creatinine (SCR) ≤140 μmol/L
Liver function
ALT and AST <1.5 times the upper limit of normal (ULN), bilirubin <1.5×ULN
Adequate function of major organs: Hematopoietic function: Hemoglobin ≥100g/L, platelets ≥90×10^9/L, white blood cells ≥4×10^9/L. Exceptions may be considered for patients with ECOG 0-1 who have a history of chronic anemia (80-100 g/L), previous low white blood cell levels (3-4×10^9/L), or reduced platelets (80-90×10^9/L). Liver function: ALT and AST <1.5 times the upper limit of normal (ULN), bilirubin <1.5×ULN. Renal function: Serum creatinine (SCR) ≤140 μmol/L.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06122493 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior radiation therapy disqualifies patients from enrollment.
What disease stage is eligible?
Stage ANY T or N3M0 is required.
Is there an age limit?
Yes. Patients must be 80 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages